EZH2 mutation

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. Tazemetostat, ... Read more

May 5, 2016May 5, 2016

Compound Effectively Targets Mutated Protein in B-Cell Lymphoma and Melanoma Early Study

News

A new investigational compound targeting a specific protein that is frequently mutated and malfunctioning in lymphoma and melanoma patients has shown promising results in mice cancer models. The study, “An ... Read more

January 5, 2016January 5, 2016

Potential B-cell Lymphoma Therapy Given IND Status, Enrolling Patients in Phase 2 Trial

News

Epizyme, Inc., announced that the U.S. Food and Drug Administration’s (FDA) Division of Hematology Products has approved its investigational new drug (IND) application for tazemetostat. The drug was developed to ... Read more